Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-01
2002-08-20
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S277700, C546S269400, C546S256000, C546S113000, C548S251000, C548S484000, C514S300000, C514S333000, C514S381000, C514S418000
Reexamination Certificate
active
06436965
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to compounds and pharmaceutical compositions for the treatment of diseases by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).
Many hormones and neurotransmitters modulate tissue function by elevating intracellular levels of 3′,5′-cyclic adenosine monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenyl cyclase. The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3′,5′-cyclic monophosphate (cGMP). At least seven members of the family have been described (PDE I-VII), the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11: 150-155, Nicholson et. al. (1991) TIPS, 12: 19-27, and Torphy and Undem (1991) Thorax, 46: 512-523].
The availability of PDE isotype selective inhibitors has enabled the role of PDEs in a variety of cell types to be investigated. In particular it has been established that PDE IV controls the breakdown of cAMP in many inflammatory cells, for example, basophils (Peachell P. T. et al., (1992) J. Immunol., 148: 2503-2510) and eosinophils (Dent G. et al., (1991) Br. J. Pharmacol., 103: 1339-1346) and that inhibition of this isotype is associated with the inhibition of cell activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect. Consequently PDE IV inhibitors are currently being developed as potential anti-inflammatory drugs particularly for the prophylaxis and treatment of asthma, by achieving both anti-inflammatory and bronchodilator effects.
The application of molecular cloning to the study of PDEs has revealed that for each isotype there may be one or more isoforms. PDE IV has been shown to exist in four isoforms (A, B, C and D) to date, each coded for by a separate gene in both rodents (Swinnen J. V. et al., (1989) Proc. Natl. Acad. Sci. USA, 86: 5325-5329) and man (Bolger G. et al., (1993) Mol. Cell Biol., 13: 6558-6571).
The existence of multiple PDE IVs raises the prospect of obtaining inhibitors that are selective for individual isoforms, thus increasing the specificity of action of such inhibitors. This assumes that the different PDE IV isoforms are functionally distinct. Indirect evidence in support of this comes from the selective distribution of these isoforms in different tissues (Swinnen et al., 1989; Bolger et al., 1993; Obernolte R. et al., (1993) Gene, 129: 239-247, ibid) and the high degree of sequence conservation amongst isoforms of different species.
To date, full length cDNAs for human PDE IVA, B and D (Bolger et al., 1993 ibid; Obernolte et al., 1993 ibid; Mclaughlin M. et al., (1993) J. Biol. Chem., 268: 6470-6476) and rat PDE IVA, B and D (Davis R. et al., (1989) Proc. Natl. Acad. Sci. USA, 86: 3604-3608; Swinnen J. V. et al., (1991) J. Biol. Chem., 266: 18370-18377), have been reported, enabling functional recombinant enzymes to be produced by expression of the cDNAs in an appropriate host cell. These cDNAs have been isolated by conventional hybridization methods. However using this approach, only partial cDNAs for both human and rat PDE IVC have been obtained. (Bolger et al., ibid. 1993 and Swinnen et al., ibid. 1989 and International Patent Specification No. WO 91/16457.)
The design of PDE IV inhibitors for the treatment of inflammatory diseases such as asthma, has met with limited success to date. Many of the PDE IV inhibitors which have been synthesised have lacked potency and/or inhibit more than one type of PDE isoenzyme in a non-selective manner. PDE IV inhibitors that are relatively potent and selective for PDE IV, are reported to be emetic as well. Indeed this side effect has been so universal that experts have expressed their belief that the emesis experienced upon administration of a PDE IV inhibitor may be mechanism based.
The compounds described herein are potent inhibitors of PDE IV at concentrations that exhibit little or no inhibitory action on other PDE isoenzymes. These compounds inhibit the human recombinant PDE IV enzyme and also elevate cAMP in isolated leukocytes. Certain compounds prevent inflammation in the lungs induced by carrageenan, platelet-activating factor (PAF), interleukin-5 (IL-5) or antigen challenge. These compounds also suppress the hyperresponsiveness of airway smooth muscle seen in inflamed lungs. Advantageously, compounds according to the invention have good oral activity, and at orally effective doses exhibit little or none of the side-effects associated with known PDE IV inhibitors, such as rolipram. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma and other inflammatory conditions.
SUMMARY OF THE INVENTION
A compound represented by formula I:
or a pharmaceutically acceptable salt or hydrate thereof wherein:
one of Z
1
, Z
2
, Z
3
and Z
4
represents N or CR
2
and the others represent CR
2
;
a represents 0 or 1;
b represents 0, 1 or 2;
d represents 0, 1 or 2;
R
1
represents H, C
1-4
alkyl or hydroxyC
1-4
alkyl;
each R
2
is independently selected from the group consisting of:
H, halo, C
1-8
alkyl, haloC
1-8
alkyl, hydroxyC
1-8
alkyl, CN, Het, OR
a
, OC(O)N(R
b
)
2
, NR
b
C(O)R
a
, C(R
a
)
2
CO
2
R
a
, C
1-8
alkylN(R
b
)
2
, haloC
1-8
alkylN(R
b
)
2
, CO
2
R
a
, C(O)N(R
b
)
2
, SO
2
N(R
b
)
2
, S(O)
b
R
d
and NR
b
SO
2
R
d
;
each R
a
is independently selected from H, C
1-4
alkyl, C
1-4
alkylNHC
1-4
alkyl, and C
1-4
alkylN(C
1-4
alkyl)
2
, the alkyl portions of which are optionally substituted with 1-3 halo groups;
each R
b
is selected from H and C1-7alkyl, and when two R
b
's are present, they can be taken together and represent a fused ring system having 5-10 members, said ring system being saturated or containing 1-4 double bonds, and optionally including 1-3 heteroatoms selected from O, S and NR
e
;
R
d
and R
e
are independently selected from Het, C
1-7
alkyl, C
2-7
alkenyl, C
2-7
alkynyl, and C
1-7
alkyl-Het;
Het represents a 5-10 membered aromatic, partially aromatic or non-aromatic ring system containing 1-4 heteroatoms selected from O, S and N, optionally substituted on any available position with oxo, C
1-4
alkyl, halo, amino, hydroxyC
1-4
alkyl, haloC
1-4
alkyl and aminoC
1-4
alkyl;
X represents C
3-7
cycloalkyl or Ar;
and each Ar is independently selected from the group consisting of: phenyl, thienyl, thiazolyl, pyridyl, oxazolyl, tetrazolyl, pyrimidinyl, pyrazinyl and pyridazinyl,
said Ar being optionally substituted with 1-4 members selected from: halo, hydroxy, CN, C
1-4
alkyl, C
1-6
haloalkyl, C
1-6
hydroxyalkyl, OC
1-6
alkyl, OC
1-6
haloalkyl, OC
1-6
hydroxyalkyl, C
1-6
alkylOC
1-6
alkyl, C
1-6
alkylOC
1-6
haloalkyl, C(O)NH
2
, C(O)NHC
1-6
alkyl, C(O)N(C
1-6
alkyl)
2
, C
1-6
alkylOC
1-6
alkylC(O)NH
2
, CO
2
H, CO
2
C
1-6
alkyl, NHC(O)C
1-6
alkyl, NHC(O)OC
1-6
alkyl, and SO
2
C
1-6
alkyl.
Pharmaceutical compositions and methods of treatment are also included.
DETAILED DESCRIPTION OF THE INVENTION
The invention encompasses compounds represented by formula I:
as well as pharmaceutically acceptable salts and hydrates thereof wherein:
one of Z
1
, Z
2
, Z
3
and Z
4
represents N or CR
2
and the others represent CR
2
;
a represents 0 or 1;
b represents 0, 1 or 2;
d represents 0, 1 or 2;
R
1
represents H, C
1-4
alkyl or hydroxyC
1-4
alkyl;
each R
2
is independently selected from the group consisting of:
H, halo, C
1-8
alkyl, haloC
1-8
alkyl, hydroxyC
1-8
alkyl, CN, Het, OR
a
, OC(O)N(R
b
)
2
, NR
b
C(O)R
a
,
Labelle Marc
Lachance Nicolas
Macdonald Dwight
Sturino Claudio
Aulakh Charanjit S.
Merck Frosst Canada & Co.
Rose David L.
Yuro Raynard
LandOfFree
PDE IV inhibiting amides, compositions and methods of treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PDE IV inhibiting amides, compositions and methods of treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDE IV inhibiting amides, compositions and methods of treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2906486